scholarly article | Q13442814 |
P356 | DOI | 10.1182/BLOOD-2006-04-013805 |
P698 | PubMed publication ID | 16912224 |
P50 | author | Jorge Eduardo Cortes | Q60320900 |
Hagop Kantarjian | Q60394812 | ||
Francis J Giles | Q62066745 | ||
Srdan Verstovsek | Q64026418 | ||
Ayalew Tefferi | Q66370740 | ||
Taghi Manshouri | Q91467065 | ||
P2093 | author name string | Alfonso Quintás-Cardama | |
Cem Akin | |||
Jingxuan Pan | |||
Peter Lamb | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | mast cell | Q191989 |
P304 | page(s) | 315-322 | |
P577 | publication date | 2006-08-15 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation | |
P478 | volume | 109 |
Q39993475 | Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies |
Q37892475 | Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis |
Q34786462 | Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells |
Q37728667 | Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity |
Q37216023 | Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation |
Q38370943 | Current treatment options in patients with mastocytosis: status in 2015 and future perspectives |
Q36059702 | Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells |
Q54566864 | Diffuse cutaneous mastocytosis masquerading as epidermolysis bullosa. |
Q37200035 | Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition |
Q39149681 | Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins |
Q35229969 | MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells |
Q24313261 | Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells |
Q37379320 | Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. |
Q41939033 | Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice |
Q39112113 | Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα. |
Q35047163 | PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells |
Q36842503 | Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders |
Q26748784 | Pharmacological treatment options for mast cell activation disease |
Q37591364 | Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin. |
Q59810100 | Preclinical human models and emerging therapeutics for advanced systemic mastocytosis |
Q33944952 | Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl |
Q39244862 | Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation |
Q33911230 | SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. |
Q39648444 | Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia |
Q53343173 | Targeted therapy in KITD816V-positive mastocytosis: waiting for proof-of-principle. |
Q40114178 | The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation |
Q51048652 | The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells. |
Q53553773 | The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. |
Q24306212 | Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors |
Q34293285 | Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. |
Search more.